Jan 28 (Reuters) - Aeterna Zentaris Inc AEZS.TO :
* AETERNA ZENTARIS EXPANDS ORPHAN DRUG DEVELOPMENT PIPELINE WITH TARGETED IMMUNOSUPPRESSIVE THERAPEUTICS
* AETERNA ZENTARIS INC - TO DEVELOP POTENTIAL THERAPEUTIC TREATMENT OPTION FOR NEUROMYELITIS OPTICA SPECTRUM DISORDER
* AETERNA ZENTARIS - GOT WORLDWIDE RIGHTS TO MAKE, COMMERCIALIZE PRODUCTS FOR NMOSD TREATMENT FOR UP-FRONT CASH PAY OF EUR 100,000, MILESTONE PAYMENTS
* AETERNA ZENTARIS-LICENSED WORLDWIDE RIGHTS OF TARGETED, HIGHLY SPECIFIC, AUTOIMMUNITY MODIFYING PROTEINS FROM JULIUS-MAXIMILIANS-UNIVERSITY WUERZBURG